TY - JOUR T1 - Innate lymphoid cells and disease tolerance in SARS-CoV-2 infection JF - medRxiv DO - 10.1101/2021.01.14.21249839 SP - 2021.01.14.21249839 AU - Noah J. Silverstein AU - Yetao Wang AU - Zachary Manickas-Hill AU - Claudia Carbone AU - Ann Dauphin AU - Brittany P. Boribong AU - Maggie Loiselle AU - Jameson Davis AU - Maureen M. Leonard AU - Leticia Kuri-Cervantes AU - MGH COVID-19 Collection & Processing Team AU - Nuala J. Meyer AU - Michael R. Betts AU - Jonathan Z. Li AU - Bruce Walker AU - Xu G. Yu AU - Lael M. Yonker AU - Jeremy Luban Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/04/2021.01.14.21249839.abstract N2 - Risk of severe COVID-19 increases with age, is greater in males, and is associated with lymphopenia, but not with higher burden of SARS-CoV-2. It is unknown whether effects of age and sex on abundance of specific lymphoid subsets explain these correlations. This study found that the abundance of ILCs decreases more than 7-fold over the human lifespan and is lower in males than in females. After accounting for age and sex, innate lymphoid cells (ILCs), but not T cells, were lower in adults hospitalized with COVID-19, independent of lymphopenia. Among SARS-CoV-2-infected adults, ILC abundance correlated inversely with odds and duration of hospitalization, and with severity of inflammation. ILCs were also uniquely decreased in pediatric COVID-19 and did not recover during follow-up. In contrast, individuals with MIS-C had depletion of both ILCs and T cells, and both cell types increased during follow-up. In both pediatric COVID-19 and MIS-C, ILC abundance correlated inversely with inflammation. Blood ILC mRNA and phenotype tracked more closely with ILCs from lung than from other organs. Importantly, blood ILCs produced amphiregulin, a protein implicated in disease tolerance and tissue homeostasis, and the percentage of amphiregulin-producing ILCs was higher in females. These results suggest that, by promoting disease tolerance, homeostatic ILCs decrease morbidity and mortality associated with SARS-CoV-2 infection, and that lower ILC abundance accounts for increased COVID-19 severity with age and in males.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank the Massachusetts Consortium for Pathogen Readiness Specimen Collection and Processing Team listed below and members of the Yu and Luban Labs. This work was supported in part by the Massachusetts Consortium for Pathogen Readiness through grants from the Evergrande Fund and NIH grants R37AI147868 and R01AI148784 to J.L. and Ruth L. Kirschstein NRSA Fellowship F30HD100110 to N.J.S. The MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness, and the Ragon Institute of MGH, MIT and Harvard. The Pediatric COVID-19 Biorepository was supported by the National Heart, Lung, and Blood Institute (5K08HL143183 to LMY), and the Department of Pediatrics at Massachusetts General Hospital for Children (to LMY).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As part of a COVID-19 observational study, peripheral blood samples were collected from 91 adults with SARS-CoV-2 infection at the Massachusetts General Hospital and affiliated outpatient clinics. Request for access to coded patient samples was reviewed by the Massachusetts Consortium for Pathogen Readiness (https://masscpr.hms.harvard.edu/), and approved by the University of Massachusetts Medical School IRB (protocol #H00020836). Pediatric participants with COVID-19 or MIS-C were enrolled in the Massachusetts General Hospital Pediatric COVID-19 Biorepository (MGB IRB # 2020P000955); healthy pediatric controls were enrolled in the Pediatric Biorepository (MGB IRB # 2016P000949). Samples were collected after obtaining consent from the patient if 18 years or older, or from the parent/guardian, plus assent when appropriate. Demographic, laboratory, and clinical outcome data were included with the coded samples. Samples from 86 adult blood donors and 17 pediatric blood donors, either collected prior to the SARS-CoV-2 outbreak, or from healthy individuals screened at a blood bank, were included as controls.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available within the manuscript and in its supplementary information files. Bulk RNA-seq datasets generated here can be found at: NCBI Gene Expression Omnibus (GEO): GSE168212. Bulk RNA-seq data generated by previously-published studies are available from NCBI GEO: GSE131031 and GSE126107 (Ardain et al., 2019; Yudanin et al., 2019). This study did not generate unique code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. ER -